Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?

Gaëtan Devos; Gert De Meerleer; Steven Joniau

doi:10.1016/j.eururo.2019.04.016

Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer?

Eur Urol. 2019 Sep;76(3):265-267. doi: 10.1016/j.eururo.2019.04.016. Epub 2019 Apr 26.

Authors

Gaëtan Devos¹, Gert De Meerleer², Steven Joniau³

Affiliations

¹ Department of Urology, University Hospitals Leuven, Leuven, Belgium. Electronic address: gaetan.devos@uzleuven.be.
² Department of Radiotherapy, University Hospitals Leuven, Leuven, Belgium.
³ Department of Urology, University Hospitals Leuven, Leuven, Belgium.

PMID: 31031049
DOI: 10.1016/j.eururo.2019.04.016

Abstract

The role of imaging before salvage treatment of recurrent prostate cancer is controversial. Knowledge of site-specific recurrence obtained from novel imaging techniques such as prostate-specific membrane antigen-based positron emission tomography/computed tomography might provide information on the benefit of imaging before salvage therapies.

Publication types

Editorial

MeSH terms

Humans
Male
Neoplasm Recurrence, Local / diagnosis*
Neoplasm Recurrence, Local / therapy
Positron Emission Tomography Computed Tomography / methods*
Prostatic Neoplasms / diagnosis*
Prostatic Neoplasms / therapy
Salvage Therapy / methods*